MedTrace Logo

Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia

NCT04459676 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-15

No results posted yet for this study

Summary

To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia

Conditions

Interventions

DRUG

Standard of Care (SOC) + ANG-3777

Standard of Care (SOC) + ANG-3777

DRUG

Standard Of Care (SOC) + Placebo

Standard Of Care + Placebo

Sponsors & Collaborators

  • CTI Clinical Trial and Consulting Services

    collaborator OTHER

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • John Neylan, MD · Angion Biomedica

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2021-04-30
Completion
2021-04-30
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459676 on ClinicalTrials.gov